Lønning PE - Search Results

1

Mutations and polymorphisms of the p21B transcript in breast cancer.

Knappskog S, Chrisanthar R, Staalesen V, Børresen-Dale AL, Gram IT, Lillehaug JR, Lønning PE. Knappskog S, et al. Among authors: lonning pe. Int J Cancer. 2007 Aug 15;121(4):908-10. doi: 10.1002/ijc.22777. Int J Cancer. 2007. PMID: 17443496 Free article.

2

Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients.

Lønning PE, Hall K, Aakvaag A, Lien EA. Lønning PE, et al. Cancer Res. 1992 Sep 1;52(17):4719-23. Cancer Res. 1992. PMID: 1380889

3

Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen.

Anker G, Lønning PE, Ueland PM, Refsum H, Lien EA. Anker G, et al. Among authors: lonning pe. Int J Cancer. 1995 Jan 27;60(3):365-8. doi: 10.1002/ijc.2910600316. Int J Cancer. 1995. PMID: 7829246

4

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.

Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE. Aas T, et al. Among authors: lonning pe. Nat Med. 1996 Jul;2(7):811-4. doi: 10.1038/nm0796-811. Nat Med. 1996. PMID: 8673929

5

Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients.

Helle SI, Holly JM, Tally M, Hall K, Vander Stappen J, Lønning PE. Helle SI, et al. Among authors: lonning pe. Int J Cancer. 1996 Aug 22;69(4):335-9. doi: 10.1002/(SICI)1097-0215(19960822)69:4<335::AID-IJC17>3.0.CO;2-4. Int J Cancer. 1996. PMID: 8797879 Free article.

6

Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome.

Aas T, Geisler S, Paulsen T, Børresen-Dale AL, Varhaug JE, Lønning PE, Akslen LA. Aas T, et al. Among authors: lonning pe. Acta Oncol. 1996;35 Suppl 5:5-8. doi: 10.3109/02841869609083960. Acta Oncol. 1996. PMID: 9142957

7

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.

Ellis PA, Lonning PE, Borresen-Dale A, Aas T, Geisler S, Akslen LA, Salter I, Smith IE, Dowsett M. Ellis PA, et al. Among authors: lonning pe. Br J Cancer. 1997;76(4):480-5. doi: 10.1038/bjc.1997.413. Br J Cancer. 1997. PMID: 9275025 Free PMC article.

8

Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.

Lønning PE. Lønning PE. Breast Cancer Res Treat. 1998;49 Suppl 1:S45-52; discussion S73-7. doi: 10.1023/a:1006048722559. Breast Cancer Res Treat. 1998. PMID: 9797017 Review.

9

CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.

Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lønning PE, Erikstein B, Kåresen R, Gabrielsen OS, Børresen-Dale AL. Nedelcheva Kristensen V, et al. Among authors: lonning pe. Cancer Res. 1999 Jun 15;59(12):2825-8. Cancer Res. 1999. PMID: 10383140

10

Genetic variants of CYP19 (aromatase) and breast cancer risk.

Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Kåresen R, Kristensen T, Børresen-Dale AL. Kristensen VN, et al. Among authors: lonning pe. Oncogene. 2000 Mar 2;19(10):1329-33. doi: 10.1038/sj.onc.1203425. Oncogene. 2000. PMID: 10713674

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

379 results

Search Page